Literature DB >> 16151855

Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia.

Wolfgang Knabe1, Anna-Leena Sirén, Hannelore Ehrenreich, Hans-Jürg Kuhn.   

Abstract

Recombinant human erythropoietin (EPO) is neuroprotective in animal models of adult spinal cord injury, and reduces apoptosis in adult dorsal root ganglia after spinal nerve crush. The present work demonstrates that spinal cord and dorsal root ganglia share dynamic expression patterns of EPO and its receptor (EPOR) during development. C57Bl mice from embryonic days (E) 8 (E8) to E19 were studied. In spinal cord and dorsal root ganglia, EPOR expression in all precursor cells preceded the expression of EPO in subsets of neurons. On E11, EPO-immunoreactive spinal motoneurons and ganglionic sensory neurons resided adjacent to EPOR-expressing radial glial cells and satellite cells, respectively. From E12 onwards, EPOR-immunoreactivity decreased in radial glial cells and, transiently, in satellite cells. Simultaneously, large-scale apoptosis of motoneurons and sensory neurons started, and subsets of neurons were labelled by antibodies against EPOR. Viable neurons expressed EPO and EPOR. Up to E12.5, apoptotic cells were EPOR-immunopositive, but variably EPO-immunonegative or EPO-immunopositive. Thereafter, EPO-immunonegative and EPOR-immunopositive apoptotic cells predominated. Our findings suggest that EPO-mediated neuron-glial and, later, neuron-neuronal interactions promote the differentiation and/or the survival of subsets of neurons and glial cells in central as well as in peripheral parts of the embryonic nervous system. Correspondingly, expression of phospho-Akt-1/protein-kinase B extensively overlapped expression sites of EPO and EPOR, but was absent from apoptotic cells. Identified other sites of EPO and/or EPOR expression include radial glial cells that transform to astrocytes, cells of the floor plate and notochord as well as neural crest-derived boundary cap cells at motor exit points and cells of the primary sympathetic chain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16151855     DOI: 10.1007/s00429-005-0019-3

Source DB:  PubMed          Journal:  Anat Embryol (Berl)        ISSN: 0340-2061


  22 in total

1.  Erythropoietin: a novel treatment for traumatic optic neuropathy-a pilot study.

Authors:  Mohsen Bahmani Kashkouli; Farzad Pakdel; Mostafa Soltan Sanjari; Anousheh Haghighi; Marzieh Nojomi; Mohammad Hossein Homaee; Abtin Heirati
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-02       Impact factor: 3.117

2.  Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis.

Authors:  Claudia Bartels; Kira Späte; Henning Krampe; Hannelore Ehrenreich
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

3.  Initial motor axon outgrowth from the developing central nervous system.

Authors:  J P Fraher; P Dockery; O O'Donoghue; B Riedewald; D O'Leary
Journal:  J Anat       Date:  2007-09-11       Impact factor: 2.610

4.  Erythropoietin Upregulates Brain Hemoglobin Expression and Supports Neuronal Mitochondrial Activity.

Authors:  N K Singhal; K Alkhayer; J Shelestak; R Clements; E Freeman; J McDonough
Journal:  Mol Neurobiol       Date:  2018-03-01       Impact factor: 5.590

5.  Neonatal erythropoietin mitigates impaired gait, social interaction and diffusion tensor imaging abnormalities in a rat model of prenatal brain injury.

Authors:  Shenandoah Robinson; Christopher J Corbett; Jesse L Winer; Lindsay A S Chan; Jessie R Maxwell; Christopher V Anstine; Tracylyn R Yellowhair; Nicholas A Andrews; Yirong Yang; Laurel O Sillerud; Lauren L Jantzie
Journal:  Exp Neurol       Date:  2017-12-26       Impact factor: 5.330

6.  Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury.

Authors:  Shenandoah Robinson; Jesse L Winer; Justin Berkner; Lindsay A S Chan; Jesse L Denson; Jessie R Maxwell; Yirong Yang; Laurel O Sillerud; Robert C Tasker; William P Meehan; Rebekah Mannix; Lauren L Jantzie
Journal:  J Neurosurg Pediatr       Date:  2016-02-19       Impact factor: 2.375

7.  Localization of erythropoietin in and around growing cartilage.

Authors:  Ward De Spiegelaere; Pieter Cornillie; Wim Van den Broeck
Journal:  Mol Cell Biochem       Date:  2009-11-12       Impact factor: 3.396

8.  Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Manuela Mengozzi; Ilaria Cervellini; Paolo Bigini; Sara Martone; Antonella Biondi; Rosetta Pedotti; Barbara Gallo; Sara Barbera; Tiziana Mennini; Mariaserena Boraso; Marina Marinovich; Edwige Petit; Myriam Bernaudin; Roberto Bianchi; Barbara Viviani; Pietro Ghezzi
Journal:  Mol Med       Date:  2008-07-30       Impact factor: 6.354

9.  Impaired synthesis of erythropoietin, glutamine synthetase and metallothionein in the skin of NOD/SCID/gamma(c)(null) and Foxn1 nu/nu mice with misbalanced production of MHC class II complex.

Authors:  L Danielyan; S Verleysdonk; M Buadze; C H Gleiter; G H Buniatian
Journal:  Neurochem Res       Date:  2009-10-14       Impact factor: 3.996

Review 10.  Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach.

Authors:  Zahra Moradi; Amirhosein Maali; Javad Sadeghi Shad; Alireza Farasat; Reza Kouchaki; Mona Moghadami; Mohamad Hosein Ahmadi; Mehdi Azad
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-16       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.